IN
Inmazeb
Atoltivimab/maftivimab/odesivimab, sold under the brand name INMAZEB, is a fixed-dose combination of three monoclonal antibodies for the treatment of ebola caused by Zaire ebolavirus. It was developed by Regeneron Pharmaceuticals and contains three human monoclonal antibodies, atoltivimab, maftivimab, and odesivimab-ebgn.
Last 30 days1Stories1Articles0Events
30-day activity pulse
Last 7d articles
1
Prior 7d baseline
0
Trend
new
Peak day
1
Peak article volume on 2026-05-17.
Last 24 hoursStories, events, map, and sources are limited to the past 24 hours. Use the Wikipedia link or the API for deeper history.
Event Timeline
No linked events in the last 24 hours.